Previous 10 | Next 10 |
enVVeno Medical press release ( NASDAQ: NVNO ): Q2 Net Loss of $7.1M The company's burn rate for the second quarter was $4.0 million, in line with previous guidance of $4.0 - $5.0 million expected cash burn per quarter. Quarter end cash and cash equivalents, and invest...
Ended the quarter with $47.2 million in cash and investments - expected to fund operations through the end of 2024, including release of topline SAVVE pivotal trial data IRVINE, CA / ACCESSWIRE / August 3, 2022 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a ...
Gainers: Inotiv ( NOTV ) +18% . IO Biotech ( IOBT ) +16% . SOPHiA GENETICS ( SOPH ) +10% . Apyx Medical ( APYX ) +9% . Rhythm Pharmaceuticals ( RYTM ) +9% . Losers: Regulus Therapeutics ( RGLS ) -14% . Aerovate...
New Current Procedural Terminology (CPT®) III code establishes a reimbursement pathway for the VenoValve The VenoValve is a potential first-in-class treatment for patients suffering from Chronic Venous Insufficiency (CVI) of the deep veins of the leg There are currently no ef...
enVVeno Medical press release (NASDAQ:NVNO): Q1 Net Loss of $5.3M The Company ended the quarter with $51.3 million in cash and cash equivalents. For further details see: enVVeno Medical reports Q1 results
- Ended the quarter with $51.3 million in cash - expected to fund operations through the end of 2024 including release of topline pivotal trial data - Ongoing advancement of SAVVE U.S pivotal trial with 20 sites available to enroll patients - Progress on development of second device ...
- Expanding patent portfolio bolsters protection of the Company's lead product -The VenoValve is a potential first-in-class treatment for patients suffering from Chronic Venous Insufficiency (CVI) of the deep veins of the leg - There are currently no effective treatments for patien...
enVVeno Medical press release (NASDAQ:NVNO): FY Net loss of $16.5M. cash and cash equivalents of $55M as of December 31, 2021 For further details see: enVVeno Medical reports FY results
Ended the Year With $55 Million in Cash Expected To Fund Operations Through the End of 2024 Including Release of Topline Pivotal Trial Data Nine (9) VenoValve Surgeries Successfully Completed and 16 Clinical Sites Currently Active in Ongoing SAVVE U.S Pivotal Trial Continued Advan...
- Previously announced promising results from the first-in-human study demonstrated sustained safety and effectiveness of the VenoValve at 1-year post-implantation - The VenoValve is currently being evaluated in ongoing SAVVE U.S pivotal trial as a potential treatment for severe deep ve...
News, Short Squeeze, Breakout and More Instantly...
enVVeno Medical Corp Com Company Name:
NVNO Stock Symbol:
NASDAQ Market:
enVVeno Medical Corp Com Website:
Live video webcast with Robert Berman, Chief Executive Officer of enVVeno Medical on Thursday, June 27 th at 4:00 PM ET IRVINE, CA / ACCESSWIRE / June 25, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatmen...
91% of Venous Ulcer Patients Evaluated at One Year Have Either Fully Healed Ulcers or Ulcers That Have Improved 100% of Venous Ulcers with a Duration of One Year or Less Prior to VenoValve Surgery Have Fully Healed 89% of Venous Ulcers with a Duration of More Than One Year Prior to Veno...
IRVINE, CA / ACCESSWIRE / June 17, 2024 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced that new interim venous ulcer healing data from the VenoValve U.S. pivotal trial will be ...